Keloid, Hypertrophic Scar, Scars, Scarring
Conditions
Brief summary
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids and hypertrophic Scars)
Detailed description
On a yearly basis, millions develop different skin scarring. These scars are a public reminder of the traumatic incident, past or present disease or a surgery which caused them. Scarring is a common consequence of wound healing process, and it is one of the most complex biological processes in human. This healing process is affected by numerous factors and thus can be disrupted, leading to pathological scarring. Pathological scarring is common in people with genetic predisposition, those undergone complex and massive surgeries, burns or those wounded in unsanitary environments. Apart from being aesthetically unpleasant, scars are associated with functional and psychosocial morbidities. Despite clinical, pathologic and pathogenic differences between keloids and hypertrophic scars, treatments are similar. Scars have a negative external impact causing social distress and impaired self-image, and as a consequence, low satisfaction rates following surgical and cosmetic procedures. The first line treatment is monthly intralesional corticosteroid injections with a response rate of 50-100% and recurrence of 50%. There are a few steroids available and used for abnormal scars treatment, including Celestone chronodose (Betamethasone acetate + Betamethasone sodium phosphate), Dexamethasone sodium phosphate, Methylprednisolone acetate, Methylprednisolone sodium succinate, Methylprednisolone hemisuccinate, Triamcinolone acetonide. Steroids are different by their hydrophilic properties, potency and half-life, although the half-life of intralesional injections is not known. Inspite of being widely used, there have never been a comparative study of the different steroid treatments.
Interventions
DRUGBetamethasone acetate + Betamethasone sodium phosphate
the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
DRUGDexamethasone sodium phosphate
the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
DRUGTriamcinolone acetonide
the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Sponsors
Tel-Aviv Sourasky Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 20 participants with at least 4 keloids * 20 participants with a hypertrophic scar of at least 11 cm length
Exclusion criteria
* current or planned pregnancy * breastfeeding women * participants suffering from diabetes mellitus or coagulation disorders * infection at planned injection sites * systemic treatment of corticosteroids, 5-fluorouracil * known allergy to any of the following: Betamethasone acetate + Betamethasone sodium phosphate, Triamcinolone acetonide, Dexamethasone sodium phosphate, Methylprednisolone acetate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient and Observer Scar Assessment Scale (POSAS) | enrollment, data will be reported through study completion an average of 1 year | For the Observer Scar Assessment Scale (OSAS), the investigators score the following parameters of each part of the scar on a scale ranging from 1 (normal skin) to 10 (worst scar imagin¬able): 'vascularization', 'pigmentation', 'thickness', 'relief', and 'pliability'. The total score on the OSAS is the sum of the scores of each item, yielding a total score ranging from 6 (best) to 60 (worst). For the patient scar assessment scale (PSAS), the participants used a scale of 1 to 10 to answer questions relating to pain, itching, color, stiffness, irregularity and thickness. The total score on the PSAS was the sum of the scores of each item, yielding a total score ranging from 6 (best) to 60 (worst) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual analogue scale (pain scale) | at each of the three treatment appointments, data will be reported through study completion an average of 1 year | 1 - paineless, 10- extremely painfull |
| Dermatologist's assessment | 3 months post last treatment, data will be reported through study completion an average of 1 year | 0- no change, 1-minor change \<5%, 2-Mild change - 25-50%, 3- Moderate Change 50-75%, 4-Significant change \> 75% |
| 3D camera | 3 months post last treatment, data will be reported through study completion an average of 1 year | improvement percentage of scar volume |
| Participant's assessment | 3 months post last treatment, data will be reported through study completion an average of 1 year | 0- no change, 1-minor change \<5%, 2-Mild change - 25-50%, 3- Moderate Change 50-75%, 4-Significant change \> 75% |
Outcome results
None listed